Effectiveness of Vojta Therapy in Motor Development of Preterm Children
Launched by UNIVERSIDAD DE MURCIA · Apr 18, 2013
Trial Information
Current as of May 30, 2025
Unknown status
Keywords
ClinConnect Summary
Premature children constitute a heterogeneous group regarding gestational age, determinants and causes of their premature birth, illnesses that occur during the neonatal period and the socio-economic status of the family. These constraints could cause an increase in the risk of development in this group of children, as well as motor abnormalities, when compared to the population of infants born at full term.
Cerebral Palsy (CP), for example, is the most common neurological disorder in this group of children. So many studies showed the association between CP and prematurity. They have point...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Experimental Group: First measurement had to be performed during the first trimester of life, from zero to three months corrected age or chronologically depending on the condition of the preterm or full-term infant. Not Diagnosed with any neurological damage and were receiving VT as a method of physiotherapy treatment.
- • The A control group: Consisted of premature children with similar base characteristics to the experimental group ones who did not receive VT but another method of physiotherapy treatment within a global programme of early intervention that included sensory-motor stimulation
- • The B control group: The control group B was formed by full term infants, without illnesses or risks. Seventy two boys and girls figured in this group. All children were treated and monitored by the Prevention, Promotion of Early Childhood Development and Early Intervention Service at the University of Murcia (Spain).
- Exclusion Criteria:
- • Experimental, A and B Groups:Parents don't signed a consent form authorizing the participation of their children in this project
About Universidad De Murcia
The Universidad de Murcia, a leading academic institution in Spain, is dedicated to advancing medical research and innovation through its clinical trial initiatives. With a strong emphasis on interdisciplinary collaboration and patient-centered approaches, the university conducts rigorous clinical studies aimed at improving health outcomes and contributing to the scientific community. Its skilled team of researchers and healthcare professionals are committed to adhering to the highest ethical standards and regulatory guidelines, ensuring that each trial not only furthers medical knowledge but also prioritizes participant safety and well-being. Through its clinical trials, the Universidad de Murcia strives to translate research findings into practical applications that enhance healthcare practices and policies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Julio PL Perez-Lopez, Phd
Study Director
Universidad de Murcia
Francisco FR J. Fernández-Rego, MD
Principal Investigator
Universidad de Murcia
María Isabel CG Casbas-Gómez, MD
Study Chair
Early Intervention Centre "Fina Navarro López" of Lorca City Council. Murcia. Spain
María Teresa MF Martínez-Fuentes, Phd
Study Chair
Universidad de Murcia
Angela DH Díaz-Herrero, PHd
Study Chair
Universidad de Murcia
Alfredo BN G. Brito de la Nuez, Phd
Study Chair
Universidad de Murcia
Tatiana Izabele SR Jaworski de Sa Riechi, PHd
Study Chair
Federal University of Parana - Brazil
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials